Otros idiomas Celltrion, Inc.

Acciones

A068270

KR7068270008

Biotecnología e investigación médica

Precio de cierre Korea S.E. Otros sitios de cotización 06/12/2024			Varia. Cinco días.	Varia. 1 de enero.
180.100,00 ^KRW	-0,50 %		-3,69 %	-10,62 %

05/12	Celltrion retirará 3 millones de acciones propias en enero	MT
04/12	La FTC de Corea del Sur impone una multa de 435 millones de KRW a Celltrion por prácticas comerciales desleales	MT

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Celltrion to Retire 3 Million Treasury Stock in January	05/12
South Korea's FTC Slaps KRW435 Million Fine on Celltrion for Unfair Business Practices	04/12
Celltrion Launches KRW100 Billion Share Buyback	22/11
BPCIA Lawsuit Against Accord's Proposed Prolia® / Xgeva® Biosimilar Filed By Amgen	21/11
MÄRKTE ASIEN/Knapp behauptet - Tokio schwächer	21/11
MÄRKTE ASIEN/Tokio leichter - sonst wenig Bewegung	21/11
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on October 25, 2024.	20/11
Celltrion, Inc.'s Equity Buyback announced on October 25, 2024, has closed with 537,924 shares, representing 0.26% for KRW 94,709.84 million.	19/11
Celltrion Presents Additional Data from Phase III Randomized Controlled Trials to Further Support Biosimilarity for CT-41 (Biosimilar Candidate of Denosumab) and CT-P47 (Biosimilar Candidate of Tocilizumab) At American College of Rheumatology Convergence 2024	18/11
Celltrion to Acquire iQone Healthcare Switzerland in European Expansion Push	15/11
Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	14/11
Trump makes Wall Street shine and depresses Europe	11/11
South Korean Shares Slide as Investors Remain Wary of New US Economic Policies After Trump Win	11/11
Trump fait briller Wall Street et déprime l'Europe	11/11
En Direct des Marchés : Stellantis freine avec Leapmotor, Continental avertit, Tesla puissance 1000	11/11
Celltrion's Net Attributable Income Plunges 61% in Q3, Sales Up 31%	11/11
FDA Accepts ABLAs For Prolia® / Xgeva® Biosimilars From Organon And Teva	07/11
Celltrion's Zymfentra Gains Broad US Insurance Coverage with New PBM Agreement	30/10
Celltrion's Zymfentra Monotherapy Shows Comparable Efficacy to Combo Therapy in IBD Study	30/10
Celltrion to Carry Out Share Buyback to Boost Value	28/10
Celltrion, Inc. announces an Equity Buyback for 537,924 shares.	25/10
Celltrion, Inc. authorizes a Buyback Plan.	25/10
Celltrion Signs Migraine Drug Development Deal with TEVA Pharmaceuticals	22/10
Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab, highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease	16/10
Celltrion Launches New Cell Line Platform for Biopharmaceutical Efficiency Boost	16/10

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Celltrion, Inc.

Acciones

A068270

KR7068270008

Biotecnología e investigación médica

Otros idiomas

Filtros